Early Phase 1 N=35 Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model
Gingivitis
Primary: Proportion of Sites That Bleed on Probing
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=185 Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
Moderate to Severe Glabellar Lines
Primary: The Proportion of Responders at Day 29 in the ILA of Glabellar Lines at Maximum Frown. — 88.3; 1.4 Adjusted percentage of responders — p=<0.0001
Phase 2 N=56 The Effect of Thiamine vs. Placebo on VO2 in Critical Illness
Critically Ill · Respiratory Failure
Primary: Change in VO2 Over Time — 4.2; 4.3 ml/kg/min
Phase 3 N=694 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
Chronic Hepatitis C · Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 96.0; 100.0; 100.0; 93.3 percentage of participants
Early Phase 1 N=15 Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
Basal Cell Carcinoma of the Skin · Recurrent Skin Cancer
Primary: Percent Change in Surgical Defect Area After the Treatment Period Using Calipers and Photographs Was Calculated — -26.8 percentage size change from baseline
N/A N=568 Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Lymphedema
Primary: Number of Participants Who Were Lymphedema-free 18 Months After Randomization — 114; 135 Participants
Phase 1 N=37 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Dose Limiting Toxicity — 0; 0 participants with DLTs
Phase 4 N=1,044 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
Hepatic Carcinoma
Primary: Incidence of Recurrence and Metastasis After Hepatectomy — 428; 155; 258; 161 Participants — p=0.0001
Phase 1 N=135 Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
Plasmodium Falciparum Malaria
Primary: Occurrence of Solicited Symptoms During a 8 Day Follow-up Period After Each Vaccination — 24; 11; 35; 15 events
Phase 1 N=32 A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Number of Participants Experiencing Adverse Events — 22 Participants
Phase 1 N=54 Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis
Herpes Labialis
Primary: Subjects With at Least One Form of Contact With Study Staff With no Herpes Labialis Outbreaks Within 119 Days of Sensitization — 62.96; 20 percentage of particpants
N/A N=90 Translating Habituation Research to Interventions for Pediatric Obesity
Pediatric Obesity · Habituation
Primary: Change of Child Body Composition — -16.1; -13.3 percentage of weight
N/A N=256 Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Breast Cancer
Primary: The M.D. Anderson Symptom Inventory (MDASI) — 23.55; 29.69; 26.28; 28.67 units on a scale
Phase 3 N=231 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Carcinoid Tumor of the Small Bowel · Neuroendocrine Tumour
Primary: Progression Free Survival (PFS) — NA; 8.5 months — p=<0.0001
N/A N=20 Evaluating the Electro Magnetic Interference of Using Tablet and Smart Phone on Leadless Pacemaker (MICRA)
Bradycardia, Atrial Tachyarrhythmia
Primary: Device Response Assessed by Asynchronous Pacing When Using a Smart Phone — 528; 547 ohms